Payment overview · 2025
General Payments
$296.51
11 reported records · 10 companies
Healthcare provider profile · identity verified
Nader F. Armanious, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · PANORAMA CITY, CA · NPI 1902023666
Verified facts
What the public records show
CMS Open Payments records show Nader F. Armanious, MD received $296.51 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.49 | 15.7% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $39.42 | 13.3% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.59 | 11.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.10 | 11.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.26 | 10.9% | 1 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $24.53 | 8.3% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$23.61 | 8.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.59 | 8.0% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.79 | 7.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.13 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $296.51 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $46.49 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.49 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $39.42 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $34.59 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.10 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.26 | 1 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 246 | 88 |
| Donepezil Hcl | Donepezil Hcl | 147 | 40 |
| Memantine Hcl | Memantine Hcl | 134 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 113 | 53 |
| Levetiracetam | Levetiracetam | 69 | 11 |
| Clonazepam | Clonazepam | 68 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 66 | 16 |
| Alprazolam | Alprazolam | 64 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 33 |
| Olanzapine | Olanzapine | 59 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 11 |
| Topiramate | Topiramate | 57 | 16 |
| Divalproex Sodium Er | Divalproex Sodium | 56 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 15 |
| Divalproex Sodium | Divalproex Sodium | 48 | suppressed |
| Metformin Hcl | Metformin Hcl | 46 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 45 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 43 | 12 |
| Omeprazole | Omeprazole | 43 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 16 |
| Trazodone Hcl | Trazodone Hcl | 42 | 17 |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Lorazepam | Lorazepam | 40 | 11 |
| Risperidone | Risperidone | 39 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | 18 |
| Simvastatin | Simvastatin | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 25 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 11 |
| Eliquis | Apixaban | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Lisinopril | Lisinopril | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 12 |
| Glipizide | Glipizide | 14 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $296.51 · 11 records | PFIZER INC. | CAPLYTA, Fintepla, KISUNLA, NURTEC ODT, PURIFIED CORTROPHIN GEL, REXULTI, Radicava, TANLOR, VALTOCO, VRAYLAR, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error